Gilead Sciences (GILD) Tops Q2 EPS by 5c, Beats on Revenue; Offers FY25 Guidance
Tweet
Share
E-mail
Get Alerts GILD Hot Sheet
Price: $128.70 -1.96%
Revenue Growth %: +4.4%
Financial Fact:
Total costs and expenses: 3.1B
Today's EPS Names:
CRMT, PKE, More
Revenue Growth %: +4.4%
Financial Fact:
Total costs and expenses: 3.1B
Today's EPS Names:
CRMT, PKE, More
Join SI Premium – FREE
Gilead Sciences (NASDAQ: GILD) reported Q2 EPS of $2.01, $0.05 better than the analyst estimate of $1.96. Revenue for the quarter came in at $7.1 billion versus the consensus estimate of $6.97 billion.
GUIDANCE:
Gilead Sciences sees FY2025 EPS of $7.95-$8.25, versus the consensus of $8.00. Gilead Sciences sees FY2025 revenue of $28.3-28.7 billion, versus the consensus of $28.7 billion.
For earnings history and earnings-related data on Gilead Sciences (GILD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Upgrades Gilead Sciences (GILD) to Buy
- Morgan Stanley Resumes American Eagle Outfitters (AEO) at Equalweight
- Unum Group (UNM) PT Raised to $110 at Barclays
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
